mobile.zenopa.com Homepage Homepage
Employment Role Location
Business Sector Advanced
Phone 01494 818 000
View company profile
Please contact the Account Manager for opportunities with this organisation

Novo Nordisk reaches IL-21 mAb licensing agreement with ZymoGenetics

Posted on 08/12/2009 in Pharmaceutical Company Product News

Novo Nordisk revealed this week that it has come to a licensing arrangement with ZymoGenetics, which will see the former firm in-license a fully-human anti-IL21 monoclonal antibody developed by the latter company.

The agreement also covers the wide range of intellectual property rights covering IL-21 mAb and the development of other IL-21 antibodies.

IL-21 mAb is a pre-IND candidate for the treatment of autoimmune and inflammatory diseases to which Novo Nordisk now has global rights.

Mads Krogsgaard Thomsen, executive vice-president and chief science officer of Novo Nordisk, said: "It was important for us to secure the worldwide rights to the IL-21 mAb project [...] and we look forward to initiating a phase 1 trial with this IL-21 mAb in 2010."

Last month, Novo Nordisk announced that it has pledged a total of three million euros (2.71 million pounds) over the next three years to the European Foundation for the Study of Diabetes.

Other news stories from 08/12/2009

Read more in the Zenopa News Archive

How this news is generated

Becky
Account Manager
for this opportunity

01494 818 026
(Mon to Fri 0830 to 1800 hours)
becky@zenopa.com

Latest News

Novo Nordisk tops endocrinology image poll

Novo Nordisk to initiate trial of diabetes drug Victoza

Novo Nordisk reports solid first quarter performance

Novo Nordisk reports positive diabetes drug trial data

Novo Nordisk commences global haemophilia survey

home | our clients | browse news | browse jobs | links | hotel directory | Valid HTML | copyright © 2010 Zenopa Ltd | terms & conditions of use